Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,010
  • Shares Outstanding, K 2,036
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,760 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -7.76
  • Number of Estimates 2
  • High Estimate -2.84
  • Low Estimate -12.69
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +2.07%
on 02/20/26
5.30 -53.58%
on 02/18/26
-1.80 (-42.25%)
since 01/20/26
3-Month
2.41 +2.07%
on 02/20/26
11.14 -77.91%
on 11/21/25
-8.08 (-76.65%)
since 11/20/25
52-Week
2.41 +2.07%
on 02/20/26
41.00 -94.00%
on 02/25/25
-32.54 (-92.97%)
since 02/20/25

Most Recent Stories

More News
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its...

MBRX : 2.46 (-8.21%)
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated...

MBRX : 2.46 (-8.21%)
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance...

MBRX : 2.46 (-8.21%)
Moleculin Launches CEO Corner Platform to Share Strategic Insights

CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company...

MBRX : 2.46 (-8.21%)
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

Register for the two-day virtual event here

AKTX : 0.2366 (+0.25%)
AIM : 1.0500 (-6.25%)
DCOY : 0.7422 (-7.04%)
BULL : 5.91 (-0.84%)
GRI : 2.49 (-2.35%)
MBRX : 2.46 (-8.21%)
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

–  Live video webcast on Wednesday, February 11 th at 1:20 PM EST    HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”),...

MBRX : 2.46 (-8.21%)
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating...

MBRX : 2.46 (-8.21%)
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 ...

MBRX : 2.46 (-8.21%)
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune...

MBRX : 2.46 (-8.21%)
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...

MBRX : 2.46 (-8.21%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 2.79
2nd Resistance Point 2.71
1st Resistance Point 2.58
Last Price 2.46
1st Support Level 2.37
2nd Support Level 2.29
3rd Support Level 2.16

See More

52-Week High 41.00
Fibonacci 61.8% 26.26
Fibonacci 50% 21.70
Fibonacci 38.2% 17.15
Last Price 2.46
52-Week Low 2.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar